PureTech Health plc (PRTC.L) LSE

124.20

-5.8(-4.46%)

Updated at June 03 04:35PM

Currency In GBp

Key Executives

Name	Title	Pay	Year Born
Robert Lyne	CEO & Director	544,572	1983
Robert S. Langer Jr.	Co-Founder & Non-Executive Director	200,654	1949
Daphne Zohar	Founder	461,930	1971
Camilla S. Graham	Senior Vice President of Medical Affairs	0	N/A
David R. Elmaleh	Co-Founder & Senior Advisor	0	1948
Charles Sherwood	COO, General Counsel & Company Secretary	0	N/A
Michael Inbar	Chief Accounting Officer	0	N/A
Spencer Ball	Executive Vice President of Human Resources	0	N/A
Anita Terpstra	Senior Vice President of Intellectual Property	0	N/A
Aleksandra Filipovic	Head of Oncology	0	N/A
Eric Elenko	Co-Founder & President	0	1973
Allison Mead Talbot	Senior Vice President of Communications & Head of Investor Relations	0	N/A
Joy Bauer	Chief Nutrition Officer	0	N/A
Lauren A. White	Chief Financial Officer	0	1979

Name

Title

Pay

Year Born

Robert Lyne

CEO & Director

544,572

1983

Robert S. Langer Jr.

Co-Founder & Non-Executive Director

200,654

1949

Daphne Zohar

Founder

461,930

1971

Camilla S. Graham

Senior Vice President of Medical Affairs

N/A

David R. Elmaleh

Co-Founder & Senior Advisor

1948

Charles Sherwood

COO, General Counsel & Company Secretary

N/A

Michael Inbar

Chief Accounting Officer

N/A

Spencer Ball

Executive Vice President of Human Resources

N/A

Anita Terpstra

Senior Vice President of Intellectual Property

N/A

Aleksandra Filipovic

Head of Oncology

N/A

Eric Elenko

Co-Founder & President

1973

Allison Mead Talbot

Senior Vice President of Communications & Head of Investor Relations

N/A

Joy Bauer

Chief Nutrition Officer

N/A

Lauren A. White

Chief Financial Officer

1979

Description

PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions. It also provides hematopoietic stem cell based therapies for patients with blood cancer; a voice-based technology platform to detect voice changes linked to health conditions; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100 to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210 to treat solid tumors; Glyph, a synthetic lymphatic targeting chemistry platform; Orasome technology to enable the oral administration of macromolecule therapeutic payloads; meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases; and Alivio technology platform for inflammation-targeted disease immunomodulation. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.